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OBJECTIVES: The ability of endosonography to diagnose a
variety of gastrointestinal pathology has been significantly
advanced with the introduction of endoscopic ultrasound–
guided fine needle aspiration (EUS-FNA) biopsy. EUS-
FNA technology can also be applied to the evaluation of
non-GI disorders. The role of EUS-FNA to establish the
diagnosis of unexplained mediastinal masses has not been
previously described. The aim of this study was to deter-
mine the diagnostic accuracy, impact on subsequent
workup, and role of EUS-FNA in treating mediastinal
masses of unknown cause.
METHODS: A total of 26 patients (15 men and 11 women,
mean age 61 yr, range 39–77 yr) underwent EUS-FNA in
patients presenting with unexplained mediastinal masses at
four tertiary referral centers. Presenting symptoms included:
chest pain (10 patients), dysphagia (eight), cough (seven),
fever (six), night sweats (three), and no symptoms/abnormal
x-ray (five patients). Five of 26 patients had prior history of
cancer (three lung, one tracheal, and one esophageal).
RESULTS: Final diagnosis using EUS-FNA, surgery, au-
topsy, other diagnostic study, or long-term follow-up was
available in all patients. EUS-FNA results were classified
under three disease categories: 1) infectious, 2) benign/
inflammatory, and 3) malignant. Final diagnosis included
infectious in five patents, benign/inflammatory in nine, and
malignant in 12. EUS-FNA was successful in 21 of 26
patients (81%) for all disease categories (infectious 60%,
benign/inflammatory 78%, and malignant 92%). EUS-FNA
was successful in directing subsequent workup in 77% (20
of 26) and therapy in 73% (19 of 26). Mean EUS-FNA
passes for adequate tissue sampling was lower of nonma-
lignant disease categories (3.0 and 3.4)versus malignant
disease (4.4). No complications were seen during the course
of this study.
CONCLUSIONS: EUS-FNA in patients presenting with idio-
pathic mediastinal masses establishes the diagnosis in the
vast majority of cases, particularly for those with malignant
disease. The emergence of transesophageal EUS-FNA of the
mediastinum provides the ability to alter subsequent workup
and therapy, obviating the need for more invasive diagnostic
studies such as thoracotomy. (Am J Gastroenterol 2002;97:
2559–2565. © 2002 by Am. Coll. of Gastroenterology)
INTRODUCTION
Thoracic imaging of mediastinal masses is challenging. CT
of the chest is the current standard by which the mediasti-
num is visualized. Problems then arise as to various tissue
sampling modalities. In well-selected patients, CT-guided
fine needle aspiration (FNA), mediastinoscopy, thoraco-
scopic mediastinal biopsy, or transbronchial biopsy has been
used. Morbidity, time, and costs have limited their applica-
bility.
The advent of endoscopic ultrasonography (EUS) has
made it possible to image the GI tract and surrounding
extraluminal tissues. EUS-FNA has become the preferred
method for staging of upper GI tract cancers. The esophagus
affords an excellent acoustic window through which to scan
the mediastinum, a fact that extends the usefulness of this
examination. Recently, EUS-FNA has been shown to have
a valuable role in identifying posterior mediastinal involve-
ment when staging nongastrointestinal malignancies (1, 2).
The purpose of this study was to assess the diagnostic
accuracy of EUS-FNA on a heterogenous group of patients
presenting with idiopathic mediastinal mass lesions, and to
assess the impact of EUS-FNA on subsequent workup and
therapy.
MATERIALS AND METHODS
A total of 26 patients underwent EUS-FNA in patients
presenting with idiopathic and mediastinal masses at four
tertiary referral centers. This group included 15 men and 11
women, with a mean age of 61 yr (range 38–77 yr). Inclu-
sion criteria included age18 yr with informed consent,
absence of tissue diagnosis at the time of EUS, and final
diagnosis established. Exclusion criteria included previ-
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ously established diagnosis, inaccessible masses for EUS-
FNA, coagulopathy, or final diagnosis not available at fol-
low-up. CT was obtained in all patients before referral for
EUS, and was abnormal (demonstrating a mediastinal mass
in the absence of lymphadenopathy) in 23 of 26 patients
(89%). The remaining three patients had incidental mass
found within the mediastinum on EUS
Presenting symptoms included chest pain in 10 patients,
dysphagia in eight, cough in seven, fever in six, night sweats
in three, and no symptoms/abnormal x-ray in five. Five of 26
patients had a prior history of cancer, including three pa-
tients with lung cancer, one with laryngeal cancer, and one
with esophageal cancer, but were believed to be free of
disease after surgical therapy (16 months to 3.5 yr before
EUS). Final diagnosis using EUS-FNA, surgery, autopsy,
and other diagnostic study or long-term follow-up was
available in all patients. EUS FNA results were classified
under three disease categories: 1) infectious, 2) benign/
inflammatory, and 3) malignant mediastinal.
All patients underwent radial endosonography (Olympus
EUM-20, Olympus America, Lake Success, NY) followed
by linear array endosonography (Pentax FG32-UA, Pentax,
Orangeburg, NY, or Olympus GFUC-30P). Fine needle
aspiration was accomplished using two different needle
types: a 22-gauge, 8-cm, adjustable length needle (Wilson-
Cook, Winston-Salem, NC) and a 22-gauge, 12-cm, adjust-
able length needle (GIP, Medi-Globe, Tempe, AZ). A cy-
topathologist was present in all cases to evaluate adequacy
of each EUS-FNA sample.
The impact of EUS-FNA results in terms of changing
clinical management (theoretic vs actual plan), including
eventual workup and treatment, was determined by each
endoscopist for each individual case. The change in clinical
management definition was the difference between the the-
oretical plan (pre-EUS) and the actual plan (post-EUS). As
this was a retrospective study, ability of EUS to alter sub-
sequent therapy and workup was based on a theoretical plan
in the absence of EUS (i.e., CT-FNA, mediastinoscopy, or
thoracotomy with biopsy to establish the diagnosis) and
actual plan (after EUS-FNA). The latter included the diag-
nosis of malignancy with avoidance of surgery. Patients
with nondiagnostic FNA had, by definition, failure of the
study to alter subsequent therapy and workup.
RESULTS
All 26 patients underwent successful EUS-FNA tissue sam-
pling (two to seven passes/patient). Histopathology was
determined to be adequate by a bedside cytopathologist in
all cases.
Final patient diagnosis by disease category included five
patients with benign/infectious masses, nine with inflamma-
tory masses, and 12 with malignant mediastinal masses (Fig.
1). EUS-FNA was successful in establishing the diagnosis in
21 of 26 patients (81%) for all disease categories, including
infectious in three of five patients (60%), benign/inflamma-
tory in seven of nine patients (78%), and malignant medi-
astinal in 11 of 12 patients (92%). Final diagnosis by his-
topathology and special stains (Table 1) included the
following: 1) infectious in five patients, including two ab-
scess, two histoplasmosis, and one tuberculosis (by acid-fast
staining); 2) benign/inflammatory in nine patients, including
five cysts (bronchogenic and duplication), three fibrosis, and
two nonspecific inflammatory masses; 3) malignant medi-
astinal (12 patients), including two adenocarcinoma of un-
known primary (Fig. 2–4), four metastatic lung cancer
(non–small cell and small cell), three lymphoma (Fig. 5–7),
two metastatic (tracheal and esophageal), and one papillary
carcinoma of thyroid. Patients with lymphoma were estab-
lished by presence of characteristic, small, morphologically
identical lymphocytes with high nuclear to cytoplasmic ra-
tio. Because this was suspicious for lymphoma, the bedside
cytopathologist requested samples for flow cytometry.
The five patients with duplication and bronchogenic cysts
had classic appearance by endosonography (anechoic, thin
walled structures adjacent to the esophageal lumen). FNA of
the lesion, specifically the wall, and aspiration of fluid was
performed for cytologic analysis given the presenting symp-
toms (including weight loss, chest pain, or fever). The
ability of EUS-FNA to alter subsequent workup included
three of five patients with infectious mediastinal masses
(60%), six of nine patients with benign/inflammatory me-
diastinal masses (67%), and 11 of 12 patients with malig-
nant mediastinal masses (92%). The ability of EUS-FNA to
alter subsequent therapy included three of five patients with
infectious mediastinal masses (60%), seven of nine patients
with benign/inflammatory mediastinal masses (78%), and
Figure 1. Mediastinal masses of unknown cause: final diagnosis.





EUS Final Diagnosis (%)
Alters Workup Alters Therapy
Infectious 5 3 (60%) 3 (60%)
Benign/inflammatory 9 6 (67%) 7 (78%)
Malignant mediastinal 12 11 (92%) 9 (75%)
Total 26 20 (77%) 19 (73%)
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nine of 12 patients with malignant mediastinal masses
(75%) (Table 1).
EUS-FNA passes (mean) for adequate tissue sampling
was lower in nonmalignant disease categories (3.0 and 3.4)
versus malignant disease (4.4) but did not reach statistical
significance. No complications were seen during the course
of the study.
DISCUSSION
Mediastinal mass lesions represent a heterogenous group of
tumors that can involve various components of the medias-
tinal space. They are most frequently located in the antero-
superior mediastinum (54%), with the posterior (26%) and
middle mediastinum (20%) being less frequently involved.
Figure 2. EUS demonstrating 4.2-cm mediastinal mass adjacent to the esophagus at 25-cm. LCA  left carotid artery; LSV  left
subclavian vein; RCA  right carotid artery.
Figure 3. EUS-FNA of patient in Figure 1.
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The masses that occur most commonly in each of the three
anatomic subdivisions and the relative incidence with which
they occur are shown in Table 2 (3). In the anterosuperior
mediastinum, the most frequent neoplasms are thymoma
(31%), lymphoma (23%), and germ cell tumor (17%). Pos-
terior mediastinal lesions are usually neurogenic tumors
(52%), bronchogenic cysts (22%), and enteric cysts (7%).
Middle mediastinal masses are usually pericardial cysts
(35%), lymphomas (21%), and bronchogenic cysts (15%).
Overall, malignant neoplasms represent 25–42% of medi-
astinal masses (4). Because of the characteristic location of
many mediastinal masses, the site of the mass establishes a
useful differential diagnosis that aids in planning the diag-
nostic evaluation.
Imaging-guided percutaneous transthoracic biopsy has
become widely accepted. CT, an effective minimally inva-
sive technique for the diagnosis of a variety of intrathoracic
lesions that are otherwise not readily accessible, has been
the preferred guidance modality for difficult parenchymal,
hilar, and mediastinal lesions. The major drawback of CT
guided biopsy is the lack of real-time guidance, the need to
perform multiple section acquisitions, the longer procedure
time, the inaccessibility of smaller lesions obstructed by
overlying bone, and a higher frequency of pneumothorax.
Alternatives to CT are more invasive. These include
thoracoscopy, limited thoracotomy, cervical mediastinos-
copy, anterior mediastinoscopy, bronchoscopy with trans-
bronchial needle biopsy, and, more recently, EUS-FNA.
Cervical mediastinoscopy has traditionally been considered
as the “gold standard” complement to CT in the preoperative
staging of the mediastinum in non–small cell lung carci-
noma. It provides access to paratracheal lymph nodes and, to
a lesser extent, subcarinal lymph nodes. The major limita-
tions are the poorly accessed aortopulmonary region, sub-
carinal lymph nodes, and the inferior mediastinum. Signif-
icant morbidity limits this high risk procedure. General
anesthesia is preferred by the thoracic surgeon to provide
better control and flexibility in terms of surgical manipula-
tion. Anterior mediastinal masses may cause airway ob-
struction and cardiovascular collapse after induction of an-
esthesia. Contraindications include superior vena cava
obstruction, tracheal deviation, and aneurysm of the thoracic
aorta. Complications occur in up to 3.0%. Hemorrhage and
pneumothorax are the most common. Not uncommon are
recurrent laryngeal nerve injury, mediastinitis, hemothorax,
and chylothorax (5). Inpatient recovery and cost further
limit this modality.
Recently, it has been shown that EUS may be used to
Figure 4. Histology of patient in Figures 1 and 2 demonstrating
adenocarcinoma.
Figure 5. EUS depicting a 4-cm mediastinal mass in a patient presenting with dysphagia and chest pain.
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image the posterior mediastinum to evaluate periesophageal
masses or to detect lymphadenopathy in patients with
esophageal or non–small cell lung cancer (6). EUS has been
demonstrated to be superior to CT scanning in diagnosing
local metastatic lymph nodes in patients with esophageal
cancer (7, 8). EUS-FNA has also been shown to detect
mediastinal sarcoidosis, silicoanthracosis, histoplasmosis,
and retrosternal goiters (9).
Unlike previously published articles on EUS-FNA of
mediastinal masses and lymph nodes (2, 4, 10–12), our
report details the evaluation and tissue sampling of nongas-
trointestinal lesions. Although some diagnoses demon-
strated lymphatic origin, all cases had pre-EUS CT describ-
ing the mass lesions in the absence of lymphadenopathy.
The above-mentioned articles (2, 4, 10–12) collectively
reported on only 29 patients with mediastinal masses, a
number similar to that in our current report.
In a comprehensive report on EUS-FNA, Giovannini et
al. (4) described the results of 141 consecutive patients,
which included 18 with mediastinal masses. The accuracy
for this indication was reportedly 89%. In their report,
Hunerbein et al. (2) presented 25 patients with mediastinal
lesions, including six patients with nonlymph node masses,
all correctly diagnosed by EUS-FNA. Unlike our study, no
attempt was made to describe the impact of accurate EUS
Figure 6. EUS-FNA of patient represented in Figure 4.
Figure 7. Histology of patient in Figures 4 and 5, demonstrating
large cell lymphoma.
Table 2. Anatomic Location of Primary Tumors and Cysts of
the Mediastinum
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tissue sampling. Several unique features of endosonography
make it favorable when specifically compared with CT
imaging. Real-time visualization during the procedure per-
mits continuous imaging assessment. EUS uses a multipla-
nar capability, which allows use of an oblique, angled ap-
proach if necessary. CT is limited somewhat by volume
effects that occur because of discrete scan thickness. This is
exemplified when attempting to visualize the region of the
left atrium and the aortopulmonary window. In addition,
problems with inadequate contrast or streak artifact gener-
ated from soft tissue-air interfaces with the main bronchi
and trachea are not present with endosonography. Addition-
ally, the principal complication of CT-guided biopsy is
pneumothorax occurring in 25–43% of patients, which is
somewhat higher than the average rate of approximately
25–30% after fluoroscopically guided thoracic biopsy (13).
In a recent report by Panelli et al. (14), EUS was de-
scribed to assist in the evaluation of mediastinal masses in
33 patients. Of these, only 25 had EUS-FNA. Three of these
had a diagnosis of malignancy established by standard en-
doscopic biopsy, whereas eight others had FNA of malig-
nant mediastinal lymph nodes. The remaining 14 patients
had mediastinal masses diagnosed by EUS-FNA. The au-
thors postulated that EUS-FNA provided a less invasive
modality in establishing the diagnosis of mediastinal
masses.
We successfully used EUS-FNA to obtain diagnostic
biopsies in 26 consecutive patients with idiopathic medias-
tinal masses. Our results show that EUS-FNA is a safe and
effective guidance modality for transesophageal biopsy of
mediastinal lesions. In fact, we were able to perform EUS-
FNA with an overall accuracy of 81% for defining the cause
of the mediastinal mass. A recent study to evaluate nodal
spread in non–small cell lung cancer used EUS-FNA to
accurately differentiate benign from malignant nodal in-
volvement in 84% of patients (6). These recent descriptions
of real-time evaluation of mediastinal lesions further
strengthen the clinical utility of this imaging technique.
Performance of EUS-FNA relies heavily upon skilled
endosonographers. A fundamental knowledge of the medi-
astinal anatomy and pathology that are unique to each com-
partment may help in determining the etiology (Table 3).
With the exclusion of sampling error, it is unclear why the
yield for malignant mediastinal lesions was higher than that
for the benign/inflammatory or the infectious groups. This
may have been the result of more FNA needle passes in
malignant (mean 4.4) compared with benign (mean 3 and
3.4) disease categories. It is our experience that in patients
with high index of suspicion for malignancy, either on the
basis of clinical presentation or atypical cells obtained on
initial FNA passes, more aggressive tissue sampling is per-
formed. In our experience, FNA of any organ or tissue
should be performed with an attendant cytopathologist or
cytotechnologist who can readily examine specimens as
they are aspirated. It is generally agreed that immediate
feedback regarding the adequacy of aspirated materials for
pathological diagnosis decreases the chance of a false neg-
ative diagnosis.
We determined that the ability of EUS-FNA affected
subsequent workup and therapy in 73% and 71% of patients,
respectively. No complications occurred as a result of EUS-
FNA. Specifically, there were no cases of mediastinitis as a
result of transesophageal bacterial migration, contrary to
what one might expect. Furthermore, no patients received
prophylactic antibiotics, including the two patients with
mediastinal abscesses. Although we cannot recommend the
routine use of antibiotics, it seems prudent to use prophy-
lactic antibiotics if the preprocedural index of suspicion for
bacterial contamination is high (i.e., cystic lesions).
Perhaps the only limitation of EUS are the regions of the
anterior mediastinum and the contralateral trachea, both of
which are of primary concern in patients with suspected
lung cancer. This may have an impact on the role of EUS-
FNA in preoperative staging of the mediastinum. Therefore,
EUS-FNA should be considered in all patients with suspi-
cious posterior mediastinal lesions and in those patients with
an indeterminate result on CT (13). Anterior mediastinal
lesions can be visualized in contrast to lymph nodes in this
area because of marked size differences, and these masses
are invariably paraesophageal (no air artifact between lesion
and esophageal wall). Mediastinoscopy should be reserved
for patients with enlarged anterior masses or for patients
with suspicious lesions that are not successfully sampled by
EUS.
The current role of EUS-FNA to assess the mediastinum
is limited by the availability of this application, combined
with a lack of awareness of the technique on the part of
thoracic surgeons and pulmonologists. As clinical algo-
rithms regarding specific indications validate this approach,
Table 3. Density and Topographical Approach for Classifying Mediastinal Masses
Location Lipidic Liquid Vascular Soft Tissue Misc
AM Thymolipoma Thymic/Pleural/pericardic cysts Goiter adenoma
Thymoma
MM Bronchogenic cyst Aortic arch aneurysm Lymph node
PM Neurinoma, neurofibroma Meningocele Descending aortic
aneurysm
Thrombotic aneurysm




AM  Anterior mediastinum; Misc  miscellaneous; MM  middle mediastinum; PM  posterior mediastinum.
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it is likely that EUS-FNA of idiopathic mediastinal lesions
will play an increasing role.
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